Advertisement
UK markets closed
  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     
  • FTSE 250

    20,442.35
    -56.35 (-0.27%)
     
  • AIM

    772.57
    +0.19 (+0.02%)
     
  • GBP/EUR

    1.1827
    +0.0005 (+0.05%)
     
  • GBP/USD

    1.2641
    -0.0019 (-0.15%)
     
  • Bitcoin GBP

    50,750.06
    -81.79 (-0.16%)
     
  • CMC Crypto 200

    1,322.10
    -38.23 (-2.81%)
     
  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     
  • DOW

    39,150.33
    +15.53 (+0.04%)
     
  • CRUDE OIL

    80.59
    -0.70 (-0.87%)
     
  • GOLD FUTURES

    2,334.70
    +3.50 (+0.15%)
     
  • NIKKEI 225

    38,596.47
    -36.53 (-0.09%)
     
  • HANG SENG

    18,028.52
    -306.78 (-1.67%)
     
  • DAX

    18,163.52
    -90.68 (-0.50%)
     
  • CAC 40

    7,628.57
    -42.77 (-0.56%)
     

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., May 06, 2024--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time.

A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240506671205/en/

Contacts

Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com